| Schedule of Other Operating Income and Expenses |
| | | | | | | | | | | | | | | | | | | JPY (millions)
For the Year Ended March 31 | | 2024 | | 2025 | | 2026 | Other operating income: | | | | | | | Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26) | ¥ | — | | | ¥ | 2,390 | | | ¥ | — | | | Gain on sales of property, plant and equipment and investment property | 144 | | | 363 | | | 165 | | | Gain on divestment of business to Teva Takeda Yakuhin | 588 | | | 4,117 | | | — | | | Gain on divestment of business and subsidiaries (Note 18) | 7,243 | | | 6,081 | | | 18,265 | | | | | | | | | | | | | | | | | | | | | Other | 11,404 | | | 13,262 | | | 6,318 | | | Total | ¥ | 19,379 | | | ¥ | 26,212 | | | ¥ | 24,747 | | | | | | | | Other operating expenses: | | | | | | | Donations and contributions | ¥ | 7,009 | | | ¥ | 7,663 | | | ¥ | 6,866 | | | Restructuring expenses (Note 22) | 81,358 | | | 128,133 | | | 70,818 | | | | | | | | | Change in fair value of financial assets and liabilities associated with contingent consideration arrangements (Note 26) | 20,757 | | | 1,788 | | | 1,006 | | | | | | | | | Valuation reserve for pre-launch inventories (reversal) | 11,052 | | | (7,313) | | | 50,984 | | | Impairment of assets held for sale (Note 18) | 1,685 | | | 6,812 | | | 1,363 | | | Provisions for legal proceedings related to AMITIZA (Note 31) | — | | | — | | | 403,478 | | | Other | 84,666 | | | 69,650 | | | 24,466 | | | Total | ¥ | 206,527 | | | ¥ | 206,733 | | | ¥ | 558,979 | |
|